"Steve is a recognized leader in the biotechnology industry and brings more than 30 years of successful company-building experience," said Laurence Reid, Ph.D., president and chief executive officer of Warp Drive Bio. "We are thrilled to welcome Steve to our team."
Mr. Holtzman comes to Warp Drive Bio as the current chief executive officer for Decibel Therapeutics, a company focused on discovering and developing new medicines to protect, repair and restore hearing. Prior to Decibel, he served as the executive vice president, corporate development at Biogen, Inc., where he lead the leadership team through six new drug approvals. Mr. Holtzman also held positions at Infinity Pharmaceuticals, Inc., where he served as founder, chief executive officer and chair of the board of directors. Previously, he was the chief business officer of Millennium Pharmaceuticals, now Takeda Oncology and prior to that a founder, board member and executive vice president of DNX Corporation. Mr. Holtzman is a member of the boards of directors for PMV Pharma, Visterra, Humatics, The Sync Project and Molecular Partners. He is also currently a trustee of the Berklee College of Music and has previously served on the board of trustees for the Hastings Center for Ethics and the Life Sciences. From 1996 to 2001, he served as a Presidential appointee to the U.S. National Bioethics Advisory Commission. He received his B.A. in philosophy from Michigan State University and his B.Phil. graduate degree in philosophy from Corpus Christi College, Oxford University, as a Rhodes Scholar.
"By harnessing novel mechanisms that exist in nature, Warp Drive Bio is poised to advance truly ground-breaking medicines with enormous potential value for patients," said Mr. Holtzman. "I am very excited to work with such a talented and passionate group as they continue to search for solutions to many of the unmet medical needs the world continues to face."
About Warp Drive Bio
Warp Drive Bio is exploiting the molecules and mechanisms of nature to create transformative medicines. The company operates on the core principle that nature is the world's most powerful inventor of new drugs, unconstrained by the mechanistic and synthetic limitations of transitional medicinal chemistry. Warp Drive Bio is deploying its proprietary Genome Mining and SMART (Small Molecule Assisted Receptor Targeting) platforms to discover novel medicines that have the potential to make a significant difference in patients' lives. The company was launched in 2012 through a strategic partnership with Sanofi and with financing from Third Rock Ventures and Greylock Partners. For more information, please visit www.warpdrivebio.com.
View source version on businesswire.com: http://www.businesswire.com/news/home/20161017005365/en/
Source: Warp Drive Bio
To read more People News articles, click here.